JPMorgan Chase & Co. Has $5.89 Million Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

JPMorgan Chase & Co. increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 95.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,609 shares of the company's stock after acquiring an additional 237,260 shares during the period. JPMorgan Chase & Co. owned about 0.71% of Replimune Group worth $5,893,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of REPL. State Street Corp raised its holdings in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in Replimune Group during the fourth quarter valued at about $7,399,000. Rosalind Advisors Inc. bought a new position in Replimune Group during the fourth quarter valued at about $3,149,000. Geode Capital Management LLC raised its holdings in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after buying an additional 217,308 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Replimune Group by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock valued at $43,546,000 after buying an additional 129,601 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Performance

REPL stock traded up $0.45 during trading on Wednesday, reaching $9.16. 74,945 shares of the stock were exchanged, compared to its average volume of 867,981. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a market capitalization of $705.46 million, a P/E ratio of -2.98 and a beta of 1.26. The stock has a 50 day simple moving average of $10.54 and a 200-day simple moving average of $11.71. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REPL. JPMorgan Chase & Co. raised their target price on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright lifted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Replimune Group currently has an average rating of "Buy" and a consensus price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.